A critical appraisal of platelet glycoprotein IIb/IIIa inhibition
- 27 November 2000
- journal article
- review article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 36 (7) , 2028-2035
- https://doi.org/10.1016/s0735-1097(00)00979-7
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofibanThe Lancet, 1999
- Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa ReceptorsNew England Journal of Medicine, 1999
- Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T LevelsNew England Journal of Medicine, 1999
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable AnginaNew England Journal of Medicine, 1998
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1998
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic AgentsaAnnals of the New York Academy of Sciences, 1991